Calendar
Top-down
A look at earnings from the view of macro-economists and market technicians
Market Overview
Heat Map
Sentiment
Technicals
Retail Sales
Pricing
Manu-facturing
Economic Cycle
Bottom-up
A bottom-up view of earnings from professional equity analysts
Earnings Highlights
Date Trades
Earnings News
Pivots
Earnings Cycle
Sector Analysis
Investor
Trader
Support
Documentation, research, and support for the information provided
Indicators
Results
About Us
Library
Contact Us
Plays
Score
Grade
Sign In
Sign In
or
Register
Forgot Password?
OR
Sign in using:
Don't have an account?
Register
CRSP
$50.50
Crispr Therapeutics Ag
($.11)
(.22%)
CRSP
Earnings Whisper ®
N/A
4th Quarter December 2022
Consensus: ($2.30)
Revenue: $7.12 Mil
Tuesday
Jan 31
4:00 PM ET
Score
Grade
Tweet
Share
Watch
Sentiment
Analysts
Sentiment
Analysts
Tweet
Share
Watch
Latest EPS
Tuesday, November 1, 2022
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results
What do you expect when CRSP reports earnings?
Beat
Meet
Miss
Where is CRSP's stock price going from here?
Up
Flat
Down
Analysts
Score
Grade
Sentiment
Analysts
Pivots
Resistance
$53.59
$52.43
$51.46
$50.30
Support
$49.33
$48.17
$47.20
Tweet
Trends
Short-term Price
Intermediate-term Price
Long-term Price
Investors' Sentiment
Analysts' Sentiment
Earnings Estimates
Growth
Description
CRISPR Therapeutics AG is a gene-editing company. It focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.
Expectations
›
Crispr Therapeutics Ag
